{"hands_on_practices": [{"introduction": "This first practice establishes a clear, quantitative foundation for distinguishing between haploinsufficiency and dominant negative effects. Using basic probability, we will model a simple homodimeric protein to derive the expected cellular activity under each pathogenic mechanism. This exercise [@problem_id:5069522] precisely demonstrates why a mutant protein that 'poisons' a complex has a much more severe impact than one that is simply absent.", "problem": "A gene encodes a homodimeric protein whose cellular activity is normalized to a value of $1$ in a cell producing only wild-type subunits. Consider a heterozygous missense variant that produces mutant subunits which still incorporate into the dimer. Assume the following fundamental conditions:\n- Both alleles are expressed equally, so the fraction of mutant subunits among all monomers is $p$, and the fraction of wild-type subunits is $1-p$.\n- Dimer assembly is random, and the identities of the two subunits in a dimer are independent draws from the monomer pool.\n- In a dominant negative model, any dimer containing at least one mutant subunit is inactive because a single mutant subunit poisons the dimer.\n- In a haploinsufficiency model, subunits contribute independently and linearly to total activity; the activity of a dimer is proportional to the number of wild-type subunits it contains.\n\nUsing only these assumptions and basic probability, derive the normalized expected activity under each model as a function of $p$. Then, for a heterozygous state with equal expression from each allele, take $p=\\tfrac{1}{2}$ and compute the ratio $R$ of dominant negative activity to haploinsufficiency activity. Provide $R$ as a single number. No rounding is required.", "solution": "The problem requires the derivation of normalized expected cellular protein activity under two distinct genetic models, haploinsufficiency (HI) and dominant negative (DN), as a function of the fraction of mutant subunits, $p$. Subsequently, we must compute the ratio of these activities for the specific case of a heterozygote with equal allele expression, where $p = \\frac{1}{2}$.\n\nFirst, we establish the probabilistic framework for the formation of the three possible homodimer types: wild-type/wild-type (WT/WT), wild-type/mutant (WT/M), and mutant/mutant (M/M). The fraction of wild-type subunits in the monomer pool is $(1-p)$, and the fraction of mutant subunits is $p$. Dimer assembly is a random process of drawing two subunits with replacement from this pool.\n\nThe probabilities for each dimer type are given by the binomial distribution:\n- The probability of forming a WT/WT dimer is $P(\\text{WT/WT}) = (1-p) \\times (1-p) = (1-p)^2$.\n- The probability of forming an M/M dimer is $P(\\text{M/M}) = p \\times p = p^2$.\n- The probability of forming a WT/M heterodimer is $P(\\text{WT/M}) = (1-p) \\times p + p \\times (1-p) = 2p(1-p)$.\nThe sum of these probabilities is $(1-p)^2 + 2p(1-p) + p^2 = ( (1-p) + p )^2 = 1^2 = 1$, as expected.\n\nNext, we define the activity of each dimer type under the two models, subject to the normalization condition that a cell with only wild-type subunits ($p=0$) has a total activity of $1$. In such a cell, only WT/WT dimers exist, so we normalize the activity of a single WT/WT dimer to $1$.\n\n**Haploinsufficiency (HI) Model**\nIn this model, the activity of a dimer is proportional to the number of wild-type subunits it contains. Let the activity of a dimer be $A_{\\text{HI}} = k \\times (\\text{number of WT subunits})$.\n- A WT/WT dimer has $2$ WT subunits. Its activity is $A_{\\text{HI, WT/WT}} = k \\times 2$. From our normalization, $A_{\\text{HI, WT/WT}} = 1$. Therefore, $2k = 1$, which gives $k = \\frac{1}{2}$.\n- A WT/M dimer has $1$ WT subunit. Its activity is $A_{\\text{HI, WT/M}} = k \\times 1 = \\frac{1}{2}$.\n- An M/M dimer has $0$ WT subunits. Its activity is $A_{\\text{HI, M/M}} = k \\times 0 = 0$.\n\nThe total expected activity, $E_{\\text{HI}}(p)$, is the sum of the activities of each dimer type weighted by their respective probabilities:\n$$E_{\\text{HI}}(p) = P(\\text{WT/WT}) \\cdot A_{\\text{HI, WT/WT}} + P(\\text{WT/M}) \\cdot A_{\\text{HI, WT/M}} + P(\\text{M/M}) \\cdot A_{\\text{HI, M/M}}$$\n$$E_{\\text{HI}}(p) = (1-p)^2 \\cdot 1 + 2p(1-p) \\cdot \\frac{1}{2} + p^2 \\cdot 0$$\n$$E_{\\text{HI}}(p) = (1-p)^2 + p(1-p)$$\nFactoring out $(1-p)$:\n$$E_{\\text{HI}}(p) = (1-p) \\left[ (1-p) + p \\right]$$\n$$E_{\\text{HI}}(p) = (1-p) \\cdot 1 = 1-p$$\nThus, the normalized expected activity under the haploinsufficiency model is $E_{\\text{HI}}(p) = 1-p$.\n\n**Dominant Negative (DN) Model**\nIn this model, any dimer containing at least one mutant subunit is inactive. This means only the pure WT/WT dimer is active.\n- The activity of a WT/WT dimer is $A_{\\text{DN, WT/WT}} = 1$ (from normalization).\n- The activity of a WT/M dimer is $A_{\\text{DN, WT/M}} = 0$ (as it contains one mutant subunit).\n- The activity of an M/M dimer is $A_{\\text{DN, M/M}} = 0$ (as it contains two mutant subunits).\n\nThe total expected activity, $E_{\\text{DN}}(p)$, is:\n$$E_{\\text{DN}}(p) = P(\\text{WT/WT}) \\cdot A_{\\text{DN, WT/WT}} + P(\\text{WT/M}) \\cdot A_{\\text{DN, WT/M}} + P(\\text{M/M}) \\cdot A_{\\text{DN, M/M}}$$\n$$E_{\\text{DN}}(p) = (1-p)^2 \\cdot 1 + 2p(1-p) \\cdot 0 + p^2 \\cdot 0$$\n$$E_{\\text{DN}}(p) = (1-p)^2$$\nThus, the normalized expected activity under the dominant negative model is $E_{\\text{DN}}(p) = (1-p)^2$.\n\n**Ratio Calculation for Heterozygous State**\nFor a heterozygous state with equal expression from both alleles, the proportion of mutant subunits is $p = \\frac{1}{2}$. We now compute the activities for this specific case.\n\n- HI activity at $p=\\frac{1}{2}$:\n$$E_{\\text{HI}}\\left(\\frac{1}{2}\\right) = 1 - \\frac{1}{2} = \\frac{1}{2}$$\n- DN activity at $p=\\frac{1}{2}$:\n$$E_{\\text{DN}}\\left(\\frac{1}{2}\\right) = \\left(1 - \\frac{1}{2}\\right)^2 = \\left(\\frac{1}{2}\\right)^2 = \\frac{1}{4}$$\n\nThe problem asks for the ratio $R$ of the dominant negative activity to the haploinsufficiency activity.\n$$R = \\frac{E_{\\text{DN}}(1/2)}{E_{\\text{HI}}(1/2)} = \\frac{1/4}{1/2}$$\n$$R = \\frac{1}{4} \\times \\frac{2}{1} = \\frac{2}{4} = \\frac{1}{2}$$\nThe ratio $R$ is $\\frac{1}{2}$.", "answer": "$$\\boxed{\\frac{1}{2}}$$", "id": "5069522"}, {"introduction": "Building on the quantitative model, this practice explores a concrete biological scenario where the specific nature of a mutation dictates its pathogenic effect. By analyzing two different truncating variants in a homodimeric enzyme, you will learn how molecular rules, such as nonsense-mediated decay (NMD) and the integrity of protein domains, determine whether a mutation causes simple haploinsufficiency or a more severe dominant negative phenotype [@problem_id:5069473]. This case study is crucial for developing the diagnostic reasoning needed to interpret genetic data.", "problem": "A gene, called ALPX, encodes a homodimeric enzyme. Each functional enzyme is a symmetric dimer of two identical monomers; catalysis requires residues within a C-terminal catalytic domain, and dimerization is mediated by an N-terminal coiled-coil interaction domain. A clinical laboratory investigates two truncating variants in ALPX found in unrelated heterozygous patients. Variant V1 introduces a premature termination codon (PTC) located approximately $100$ nucleotides upstream of the last exon–exon junction. Variant V2 introduces a PTC within the terminal exon such that the truncated protein retains the N-terminal interaction domain but lacks the C-terminal catalytic domain.\n\nYou may assume the following foundational principles. The Central Dogma of molecular biology states that genes are transcribed into messenger ribonucleic acid (mRNA) and translated into protein, and under typical conditions the abundance of a gene product is proportional to allele dosage. Premature termination codons more than $50$–$55$ nucleotides upstream of the last exon–exon junction generally trigger nonsense-mediated decay (NMD) that reduces the mutant mRNA abundance. Haploinsufficiency is a mechanism in which a single wild-type allele does not supply sufficient functional product to meet the physiological threshold for normal function. A dominant negative mechanism occurs when a mutant protein interferes with the function of the wild-type protein, often by incorporation into multimers or complexes, thereby reducing the activity more than expected from a simple reduction of dosage.\n\nIn cell-based assays under conditions where both alleles are expressed at similar rates, the heterozygote with V1 shows mild reduction in enzyme activity and mild phenotype, whereas the heterozygote with V2 shows severe reduction in enzyme activity and severe phenotype, approaching that observed in ALPX homozygous null models. Assume random assembly of dimers from the available monomer pool when dimers can form, and that mixed dimers comprised of one wild-type monomer and one truncated monomer are catalytically inactive if the truncated monomer lacks catalytic residues.\n\nWhich of the following statements best explains how phenotypic severity in heterozygotes informs assignment of haploinsufficiency versus dominant negative mechanism, and why truncation location relative to interaction and catalytic domains is critical? Select ALL correct options.\n\nA. A heterozygote producing a truncated monomer that retains the interaction domain but lacks catalytic residues is expected to show more severe activity loss than a heterozygote with an early PTC that triggers nonsense-mediated decay, supporting a dominant negative mechanism in the former and haploinsufficiency in the latter.\n\nB. If a truncation removes the interaction domain but leaves the catalytic domain intact, the mechanism is necessarily dominant negative because the mutant monomer will always sequester substrate despite being unable to join the complex.\n\nC. For a homodimeric enzyme with equal expression from both alleles, when one allele produces truncated monomers that can dimerize but are catalytically inactive, the expected fraction of functional dimers in the heterozygote is $0.25$, consistent with a dominant negative effect that can be more severe than simple haploinsufficiency.\n\nD. Premature termination codons located more than $50$–$55$ nucleotides upstream of the last exon–exon junction typically trigger nonsense-mediated decay, reducing mutant mRNA and favoring a haploinsufficiency mechanism in heterozygotes, which aligns with milder phenotypes.\n\nE. Dominant negative effects are limited to structural proteins and cannot occur with enzymes, because enzymes do not form complexes that permit interference.\n\nF. The position of the truncation relative to interaction versus catalytic domains is mechanistically decisive: loss of an interaction domain reduces the likelihood of dominant negative interference, whereas retention of interaction with loss of catalytic function enhances dominant negative potential.", "solution": "The problem requires an analysis of two different mutations in a gene, ALPX, that encodes a homodimeric enzyme, to explain how the resulting phenotypes distinguish between haploinsufficiency and a dominant negative mechanism.\n\nFirst, I will validate the problem statement.\n\n### **Step 1: Extract Givens**\n-   **Gene and Protein:** A gene, ALPX, encodes a homodimeric enzyme.\n-   **Protein Structure:** Functional enzymes are symmetric dimers of two identical monomers. Monomers have an N-terminal coiled-coil interaction domain for dimerization and a C-terminal catalytic domain for catalysis.\n-   **Variants:** Two truncating variants in heterozygous patients are described.\n    -   **Variant V1:** A premature termination codon (PTC) is located approximately $100$ nucleotides upstream of the last exon–exon junction.\n    -   **Variant V2:** A PTC is located within the terminal exon. The resulting truncated protein retains the N-terminal interaction domain but lacks the C-terminal catalytic domain.\n-   **Foundational Principles:**\n    -   Central Dogma: Gene transcription to mRNA, translation to protein; product abundance is proportional to allele dosage.\n    -   Nonsense-Mediated Decay (NMD): PTCs more than $50$–$55$ nucleotides upstream of the last exon–exon junction trigger NMD, reducing mutant mRNA abundance.\n    -   Haploinsufficiency (HI): A single wild-type allele does not produce enough functional product for a normal phenotype.\n    -   Dominant Negative (DN) effect: A mutant protein interferes with the wild-type protein, reducing activity more than expected from simple dosage reduction.\n-   **Observations:**\n    -   In assays, the V1 heterozygote shows a mild reduction in enzyme activity and a mild phenotype.\n    -   The V2 heterozygote shows a severe reduction in enzyme activity and a severe phenotype, approaching that of a homozygous null.\n-   **Assumptions:**\n    -   Both alleles are expressed at similar rates (unless otherwise specified, e.g., by NMD).\n    -   Dimer assembly is random from the available monomer pool.\n    -   Mixed dimers (wild-type + truncated) are catalytically inactive if the truncated monomer lacks catalytic residues.\n\n### **Step 2: Validate Using Extracted Givens**\nThe problem statement is scientifically grounded, well-posed, and objective. It is based on fundamental and well-established principles of molecular biology and medical genetics, such as protein structure-function relationships, gene expression, nonsense-mediated decay, and mechanisms of genetic disease (haploinsufficiency, dominant negative effects). The scenario is a classic and realistic illustration of these concepts. The information provided is self-contained, consistent, and sufficient to arrive at a logical conclusion. The terminology is precise. The problem does not violate any of the invalidity criteria.\n\n### **Step 3: Verdict and Action**\nThe problem is valid. I will proceed to the solution.\n\n### **Derivation of Mechanisms for V1 and V2**\n\n**Analysis of Variant V1:**\nThe V1 allele contains a premature termination codon (PTC) approximately $100$ nucleotides upstream of the final exon-exon junction. According to the provided principles, a PTC located more than $50$–$55$ nucleotides upstream of the last exon-exon junction triggers nonsense-mediated decay (NMD). Therefore, the mRNA transcribed from the V1 allele will be targeted for degradation. This drastically reduces the amount of mutant mRNA available for translation, leading to the production of very little or no truncated protein. The cell's protein pool will consist almost exclusively of wild-type monomers produced from the single functional allele. In a heterozygote, this means the total amount of functional wild-type protein produced is approximately $50\\%$ of that in a homozygous wild-type individual. The resulting phenotype is caused by an insufficient amount of the functional enzyme, which is the definition of **haploinsufficiency**. The observation of a \"mild reduction in enzyme activity and mild phenotype\" is consistent with having approximately $50\\%$ of the normal enzyme activity.\n\n**Analysis of Variant V2:**\nThe V2 allele contains a PTC within the terminal exon. Since there are no exon-exon junctions downstream of this PTC, it does not trigger NMD. The mutant mRNA is stable and translated into a truncated protein. This protein is described as retaining the N-terminal interaction domain but lacking the C-terminal catalytic domain.\n\nLet the wild-type monomer be denoted by $W$ and the truncated V2 monomer by $M$. In the heterozygous state, assuming equal expression from both alleles, the monomer pool will consist of approximately $50\\%$ $W$ and $50\\%$ $M$. These monomers randomly assemble into dimers. The possible combinations and their probabilities are:\n-   Dimer $WW$: Formed from two wild-type monomers. Probability is $P(W) \\times P(W) = 0.5 \\times 0.5 = 0.25$. This dimer is catalytically active.\n-   Dimer $WM$ (and $MW$): Formed from one wild-type and one mutant monomer. Probability is $2 \\times P(W) \\times P(M) = 2 \\times 0.5 \\times 0.5 = 0.50$. Since the $M$ monomer lacks the catalytic domain, the problem states these mixed dimers are inactive.\n-   Dimer $MM$: Formed from two mutant monomers. Probability is $P(M) \\times P(M) = 0.5 \\times 0.5 = 0.25$. This dimer lacks any catalytic domains and is inactive.\n\nTherefore, only $25\\%$ of the total dimers formed ($WW$) are functional. The remaining $75\\%$ are non-functional. The mutant protein $M$ actively interferes with the wild-type protein $W$ by sequestering it into inactive $WM$ complexes. This is a **dominant negative** effect. A reduction of enzyme activity to $25\\%$ of normal is a severe loss, far greater than the $50\\%$ loss seen in the haploinsufficiency case. This aligns with the observation of a \"severe reduction in enzyme activity and severe phenotype.\"\n\n### **Option-by-Option Analysis**\n\n**A. A heterozygote producing a truncated monomer that retains the interaction domain but lacks catalytic residues is expected to show more severe activity loss than a heterozygote with an early PTC that triggers nonsense-mediated decay, supporting a dominant negative mechanism in the former and haploinsufficiency in the latter.**\nThis statement directly compares the situations for V2 and V1. The V2 scenario (retained interaction, no catalysis) leads to a dominant negative effect and severe activity loss (to $25\\%$). The V1 scenario (early PTC, NMD) leads to haploinsufficiency and milder activity loss (to ~$50\\%$). The statement correctly identifies the mechanisms and correlates them with the severity of activity loss as derived above.\n**Verdict: Correct.**\n\n**B. If a truncation removes the interaction domain but leaves the catalytic domain intact, the mechanism is necessarily dominant negative because the mutant monomer will always sequester substrate despite being unable to join the complex.**\nThis presents a hypothetical scenario. If the mutant monomer lacks the interaction domain, it cannot dimerize with the wild-type monomer. Thus, it cannot interfere with the formation of functional $WW$ dimers. The primary mechanism of dominant negative interference described in the problem (poisoning the multimer) is blocked. The cell would produce functional $WW$ dimers from the WT allele, resulting in ~$50\\%$ activity, which corresponds to haploinsufficiency. The claim that the monomer would \"sequester substrate\" is speculative and not the defining feature of a dominant negative effect, which involves interference with the partner protein. The assertion that the mechanism is \"necessarily dominant negative\" is false.\n**Verdict: Incorrect.**\n\n**C. For a homodimeric enzyme with equal expression from both alleles, when one allele produces truncated monomers that can dimerize but are catalytically inactive, the expected fraction of functional dimers in the heterozygote is $0.25$, consistent with a dominant negative effect that can be more severe than simple haploinsufficiency.**\nThis statement describes the V2 scenario. As calculated in the derivation, if monomer populations are equal ($50\\%$ wild-type, $50\\%$ mutant) and they randomly associate, the fraction of functional wild-type/wild-type dimers is $0.5 \\times 0.5 = 0.25$. This $75\\%$ reduction in activity is indeed more severe than the $50\\%$ reduction expected from haploinsufficiency (loss of one allele's product) and is the result of a dominant negative effect. The calculation and conclusion are correct.\n**Verdict: Correct.**\n\n**D. Premature termination codons located more than $50$–$55$ nucleotides upstream of the last exon–exon junction typically trigger nonsense-mediated decay, reducing mutant mRNA and favoring a haploinsufficiency mechanism in heterozygotes, which aligns with milder phenotypes.**\nThis statement accurately describes the general principle and its application to the V1 case. The PTC in V1 triggers NMD. The consequent reduction in mutant protein production prevents a dominant negative effect and results in haploinsufficiency, as the primary defect is simply the reduced dosage of the wild-type product. As established by comparing V1 and V2, this mechanism leads to a comparatively milder phenotype than the dominant negative effect. The statement is factually correct and relevant to the problem.\n**Verdict: Correct.**\n\n**E. Dominant negative effects are limited to structural proteins and cannot occur with enzymes, because enzymes do not form complexes that permit interference.**\nThis statement is factually incorrect. Many enzymes, including the one in this problem, are multimeric (form complexes of multiple subunits). The formation of a complex is the prerequisite for the classic dominant negative mechanism, where a mutant subunit can \"poison\" the entire complex. Dominant negative effects are well-documented for enzymes, transcription factors, and channel proteins, not just structural proteins. The premise of the problem itself contradicts this statement.\n**Verdict: Incorrect.**\n\n**F. The position of the truncation relative to interaction versus catalytic domains is mechanistically decisive: loss of an interaction domain reduces the likelihood of dominant negative interference, whereas retention of interaction with loss of catalytic function enhances dominant negative potential.**\nThis statement correctly synthesizes the core principle demonstrated by the problem. If a mutant monomer cannot interact with the wild-type monomer (e.g., loss of the interaction domain), it cannot exert a dominant negative effect via complex formation. The outcome is typically haploinsufficiency. Conversely, if the mutant monomer retains the ability to interact but is functionally dead (e.g., loss of the catalytic domain), it will interfere with wild-type partners, creating a dominant negative effect. The statement accurately captures this critical distinction.\n**Verdict: Correct.**", "answer": "$$\\boxed{ACDF}$$", "id": "5069473"}, {"introduction": "This final practice reveals the compounding severity of dominant negative effects as protein complexes grow larger. We will extend our model from a dimer to a homotetramer to calculate how quickly the population of functional complexes collapses in the presence of a mutant subunit [@problem_id:5069532]. This exercise powerfully illustrates why even a small fraction of mutant protein can be sufficient to cause disease when it interferes with the function of a higher-order oligomer.", "problem": "A single gene encodes a homotetrameric protein complex whose function is essential for a defined cellular process. According to the Central Dogma of molecular biology, Deoxyribonucleic Acid (DNA) is transcribed to Ribonucleic Acid (RNA) and translated to protein, and many proteins assemble into multimeric complexes. In oligomeric complexes, missense variants can act through dominant negative effects: mutant subunits co-assemble with wild-type subunits but render the entire complex nonfunctional if critical integrity is lost. Consider a heterozygous missense variant in this gene whose translated mutant subunits are stable and incorporate into homotetramers but produce nonfunctional complexes whenever any mutant subunit is present. Let the fraction of all translated subunits that are mutant be $p$, and assume random assembly into homotetramers with independent subunit sampling from the cellular subunit pool. \n\nUsing only the principles above, derive the fraction $F(p)$ of functional tetrameric complexes as a function of $p$. Then, suppose normal physiology requires a minimal normalized activity threshold $T = 0.25$, defined as the fraction of functional tetramers needed to maintain normal cellular function. Determine the critical mutant subunit fraction $p_{\\text{crit}}$ such that $F(p_{\\text{crit}}) = T$. Round your final numerical answer for $p_{\\text{crit}}$ to four significant figures.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n### Step 1: Extract Givens\n- The protein complex is a homotetramer, meaning it is composed of $4$ identical subunits.\n- A heterozygous missense variant produces mutant subunits.\n- Mutant subunits are stable and co-assemble with wild-type subunits.\n- A tetrameric complex is nonfunctional if it contains one or more mutant subunits.\n- Subunit assembly is random and independent.\n- $p$ represents the fraction of the total subunit pool that is mutant. Consequently, the fraction of wild-type subunits is $1-p$.\n- $F(p)$ is the fraction of assembled complexes that are functional.\n- The minimal activity threshold for normal function is $T=0.25$.\n- The critical mutant subunit fraction, $p_{\\text{crit}}$, is defined by the condition $F(p_{\\text{crit}}) = T$.\n- The final numerical answer for $p_{\\text{crit}}$ must be rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem describes a classic dominant-negative effect, a well-established pathogenic mechanism in medical genetics for multimeric proteins. The model of random subunit assembly follows basic principles of probability and is a standard approach for quantifying the impact of such mutations. The premises are consistent with molecular biology and genetics.\n- **Well-Posed:** The problem is clearly defined. It provides all necessary information: the stoichiometry of the complex (tetramer, $n=4$), the condition for functionality (zero mutant subunits), the definition of the input variable ($p$), and the target condition ($F(p_{\\text{crit}}) = 0.25$). A unique mathematical solution can be derived.\n- **Objective:** The problem statement is formulated with precise, objective language, free of ambiguity or subjective claims.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A solution will be derived.\n\nThe problem asks for the fraction of functional protein complexes, $F(p)$, and a critical value $p_{\\text{crit}}$. A complex is functional only if it is composed entirely of wild-type subunits.\n\nThe protein complex is a homotetramer, which means it is an assembly of $n=4$ subunits. The assembly process is described as random sampling with replacement from a large cellular pool of subunits. Let $p$ be the probability that a randomly selected subunit is mutant. The probability that a randomly selected subunit is wild-type is therefore $1-p$.\n\nFor a tetramer to be functional, all $4$ of its constituent subunits must be of the wild-type variety. Since the selection of each subunit is an independent event, the probability of forming a functional tetramer is the product of the probabilities of selecting a wild-type subunit for each of the $4$ positions.\n\nLet $P(\\text{WT})$ be the probability of selecting a wild-type subunit, so $P(\\text{WT}) = 1-p$.\nThe probability of selecting $4$ wild-type subunits in a row is:\n$$\nP(\\text{functional}) = P(\\text{WT}) \\times P(\\text{WT}) \\times P(\\text{WT}) \\times P(\\text{WT}) = (P(\\text{WT}))^4\n$$\nThe fraction of functional complexes, $F(p)$, is this probability.\n$$\nF(p) = (1-p)^4\n$$\nThis derivation can also be formalized using the binomial distribution. Let $k$ be the number of mutant subunits in a tetramer. The probability of having exactly $k$ mutant subunits in a complex of size $n=4$ is given by the binomial probability formula:\n$$\nP(X=k) = \\binom{n}{k} p^k (1-p)^{n-k}\n$$\nIn this case, $n=4$.\n$$\nP(X=k) = \\binom{4}{k} p^k (1-p)^{4-k}\n$$\nA complex is functional only if it has zero mutant subunits, which corresponds to $k=0$. The fraction of functional complexes $F(p)$ is therefore $P(X=0)$.\n$$\nF(p) = P(X=0) = \\binom{4}{0} p^0 (1-p)^{4-0}\n$$\nSince $\\binom{4}{0} = 1$ and $p^0=1$, this simplifies to:\n$$\nF(p) = (1-p)^4\n$$\nThis confirms the first part of the derivation.\n\nNext, we must determine the critical mutant subunit fraction, $p_{\\text{crit}}$, at which the fraction of functional complexes drops to the minimal required threshold, $T=0.25$. We set $F(p_{\\text{crit}})$ equal to $T$:\n$$\nF(p_{\\text{crit}}) = (1-p_{\\text{crit}})^4 = T\n$$\nSubstituting the given value $T=0.25$:\n$$\n(1-p_{\\text{crit}})^4 = 0.25\n$$\nTo solve for $p_{\\text{crit}}$, we take the fourth root of both sides. Since $p_{\\text{crit}}$ is a fraction between $0$ and $1$, the term $(1-p_{\\text{crit}})$ must be positive and real.\n$$\n1 - p_{\\text{crit}} = (0.25)^{1/4}\n$$\nWe can simplify the right-hand side. Note that $0.25 = \\frac{1}{4}$.\n$$\n1 - p_{\\text{crit}} = \\left(\\frac{1}{4}\\right)^{1/4} = \\frac{1^{1/4}}{4^{1/4}} = \\frac{1}{(2^2)^{1/4}} = \\frac{1}{2^{2/4}} = \\frac{1}{2^{1/2}} = \\frac{1}{\\sqrt{2}}\n$$\nNow, we can isolate $p_{\\text{crit}}$:\n$$\np_{\\text{crit}} = 1 - \\frac{1}{\\sqrt{2}}\n$$\nTo obtain the final numerical answer, we calculate this value.\n$$\n\\frac{1}{\\sqrt{2}} = \\frac{\\sqrt{2}}{2} \\approx \\frac{1.41421356}{2} \\approx 0.70710678\n$$\nTherefore,\n$$\np_{\\text{crit}} \\approx 1 - 0.70710678 = 0.29289322\n$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $2$, $9$, $2$, and $8$. The fifth significant figure is $9$, which is $5$ or greater, so we round up the fourth significant figure.\n$$\np_{\\text{crit}} \\approx 0.2929\n$$\nThis result demonstrates the potent effect of a dominant-negative mutation. Even when mutant subunits constitute less than $30\\%$ of the total pool, the functional output of the essential protein is reduced by $75\\%$, falling to the minimum threshold for normal physiology.", "answer": "$$\\boxed{0.2929}$$", "id": "5069532"}]}